NewAmsterdam Pharma Company N.V.
NAMSNASDAQHealthcare● Active
$30.95
$-0.57(-1.81%)
Market Cap$3.6B
P/E Ratio—
52W High$42.205
52W Low$17.63
NewAmsterdam Pharma Company N.V. (NAMS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NAMS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $22.50M | $45.56M | $14.09M | $102.69M | $0.00M |
| Cost of Revenue | $0.06M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $22.44M | $45.56M | $14.09M | $102.69M | $0.00M |
| Gross Margin %(computed) | 99.74% | 100.00% | 100.00% | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $141.83M | $151.41M | $159.42M | $86.74M | $28.97M |
| G&A Expenses | $106.30M | $70.45M | $37.63M | $19.51M | $4.70M |
| Total Operating Expenses | $248.13M | $221.85M | $197.06M | $106.25M | $34.98M |
| Operating Income | ($225.68M) | ($176.29M) | ($182.97M) | ($3.56M) | ($34.98M) |
| Operating Margin %(computed) | — | -386.91% | — | -3.46% | — |
| Interest Income | $27.59M | $16.88M | $10.22M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $6.80M | $0.29M | $0.41M |
| Income Before Tax | ($203.82M) | ($241.60M) | ($176.91M) | ($22.63M) | ($41.78M) |
| Income Tax Expense | $0.00M | ($0.00M) | $0.03M | $0.00M | $0.00M |
| Net Income | ($203.82M) | ($241.60M) | ($176.94M) | ($22.63M) | ($41.78M) |
| Net Margin %(computed) | -905.74% | -530.25% | — | -22.04% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.75 | $-2.56 | $-2.15 | $-1.19 | $-3.34 |
| Wtd Avg Shares | 114.40M | 94.36M | 82.16M | 18.97M | 17.75M |
| EBITDA | ($242.32M) | ($241.49M) | ($176.86M) | ($22.34M) | ($41.37M) |
| EBITDA Margin %(computed) | — | -530.00% | — | -21.75% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more NewAmsterdam Pharma Company N.V. data
About NewAmsterdam Pharma Company N.V. (NAMS) Income Statement
NewAmsterdam Pharma Company N.V. (NAMS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NAMS reported revenue of $0.02B, gross profit of $0.02B (gross margin 99.74%), and net income of ($0.20B) — a net profit margin of -905.74%.
Frequently asked questions
NAMS · 4 questionsNewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $0.02B for 2025, down 50.6% year-over-year.
NAMS revenueNAMS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08